Dabogratinib

Synonyms: TYRA-300
Dabogratinib (TYRA-300) 是一种口服有效的 FGFR3 选择性抑制剂,IC50 为 11 nM,对尿路上皮癌和实体瘤具有抗肿瘤活性,可下调 FGFR3 和 ERK1/2 信号通路,在 FGFR3 改变的异种移植模型中诱导肿瘤生长抑制与消退,并可促进软骨细胞增殖与分化,推动软骨内骨形成及整体身体生长,部分恢复长骨比例,改善颅面和脊柱形态,可用于转移性尿路上皮癌、软骨发育不全及软骨发育低下的研究。
产品编号: MS-C29778 纯度: 99.90% CAS No.: 2800223-30-5 分子式: C25H24Cl2N6O3S 分子量: 559.47
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Dabogratinib (TYRA-300) 是一种口服有效的 FGFR3 选择性抑制剂,IC50 为 11 nM,对尿路上皮癌和实体瘤具有抗肿瘤活性,可下调 FGFR3 和 ERK1/2 信号通路,在 FGFR3 改变的异种移植模型中诱导肿瘤生长抑制与消退,并可促进软骨细胞增殖与分化,推动软骨内骨形成及整体身体生长,部分恢复长骨比例,改善颅面和脊柱形态,可用于转移性尿路上皮癌、软骨发育不全及软骨发育低下的研究。

生物实验数据

生物活性 Dabogratinib (TYRA-300) is an orally active selective FGFR3 inhibitor with an IC50 of 11 nM that exhibits antitumor activity against urothelial carcinoma and solid tumors, downregulates FGFR3 and ERK1/2 signaling pathways, induces tumor growth inhibition and regression in FGFR3-altered xenograft models, promotes chondrocyte proliferation and differentiation, drives endochondral bone formation and overall body growth, partially restores long bone proportions, and improves craniofacial and spinal morphology, and can be used for research on metastatic urothelial carcinoma, achondroplasia, and hypochondroplasia.
IC50 & Target FGFR1:278 nM, FGFR2:157 nM, FGFR4:4045 nM, FGFR3:11 nM
体外研究
(In Vitro)

Dabogratinib (0.046 nM-3 μM; 2 h) 可在 RT112/84、RT112/84-V555M 和 UM-UC-14 膀胱癌细胞系中诱导 FGFR3 下游信号通路呈剂量依赖性下调 (以 pERK1/2 水平为检测指标)。
Dabogratinib 可抑制由 FGFR3 驱动的膀胱癌细胞系的活力,其 IC50 值分别为:RT112/84 细胞系 9 nM、RT112/84-V555M 细胞系 17 nM、UM-UC-14 细胞系 16 nM。

Western Blot Analysis

Cell Line: RT112/84, RT112/84-V555M, and UM-UC-14 bladder cancer cell lines
Concentration: 0.046, 0.18, 0.73, 2.9, 12, 47, 188, 750, 3000 nM
Incubation Time: 2 hours
Result: Induced a dose-dependent decrease in pERK1/2 levels in all three cell lines; showed similar dose-response patterns in gatekeeper-mutant RT112/84-V555M cell line as in RT112/84 and UM-UC-14 cell lines harboring only activating alterations.
体内研究
(In Vivo)

Dabogratinib (3-18 mg/kg; p.o.; 每日一次或两次共 21 天) 在携带 FGFR3S249C 的尿路上皮癌异种移植模型中展现出剂量依赖性的体内功效。
Dabogratinib (12.5 mg/kg; p.o.; 每日两次) 可在FGFR3::TACC3 融合尿路上皮癌异种移植模型和 FGFR3V555M 尿路上皮癌异种移植模型中诱导肿瘤消退。
Dabogratinib (8-14 mg/kg; p.o.; 每日一次共 4 周) 可在体内以剂量依赖方式提高野生型小鼠的生长速率并促进其长骨生长。
Dabogratinib (1.2 mg/kg; s.c.; 每日一次共 15 天) 可在软骨发育不全 (ACH) 的 Fgfr3Y367C/+ 小鼠模型中促进骨生长、改善骨骼比例、优化生长板结构并增大枕骨大孔尺寸。
Dabogratinib (1.8 mg/kg; s.c.; 每日一次共 21 天) 可在 HCH 的 Fgfr3N534K/+小鼠模型中增加骨长度、扩大枕骨大孔尺寸并改善椎间盘形态。

Animal Model: athymic nude (nu/nu) (female, 6 to 8 weeks old)
Dosage: 3, 6 and 9 mg/kg (twice daily); 6, 12 and18 mg/kg (once daily)
Administration: p.o.; twice daily; 21 days; p.o.; once daily; 21 days
Result: Observed no tumor growth inhibition (TGI) at 3 mg/kg twice daily; Achieved 53% TGI at 6 mg/kg twice daily, 90% TGI at 9 mg/kg twice daily, 46% TGI at 6 mg/kg once daily, 80% TGI at 12 mg/kg once daily, and 96% TGI at 18 mg/kg once daily.
Detected significant tumor volume reduction with 12, 18 mg/kg once daily and 9 mg/kg twice daily compared with vehicle.
Observed more tumor regression with 18 mg/kg once daily than erdafitinib 12.5 mg/kg twice daily.
Recorded no body weight loss in any treatment group.
Animal Model: C57BL/6J (female, 4-8 weeks of age)
Dosage: 8, 10, 12, 14 mg/kg
Administration: p.o.; once daily; 4 weeks
Result: Increased nasoanal length by 7.3% with 14 mg/kg compared with vehicle; increased tibia length by 3.9% and femur length by 5.0% with 12 mg/kg compared with vehicle. Increased tibia length by 6.4% and femur length by 8.2% with 14 mg/kg compared with vehicle.
Induced significant increases in nasoanal length, tibia length, and femur length with 8 mg/kg and 10 mg/kg compared with vehicle.
Animal Model: Tg-CMV^Cre/+ / Fgfr3^Y367C/+ (mixed male and female, 1 day of age, Achondroplasia modeling)
Dosage: 1.2 mg/kg
Administration: s.c.; once daily; 15 days
Result: Increased nasoanal length by 17.88%, tail length by 25.10%, and body weight by 52.9% compared with vehicle-treated mutant mice; increased tibia length by 33.01%, femur length by 22.55%, ulna length by 23.51%, and humerus length by 15.52% compared with vehicle. Increased skull length by 10.08%, skull width by 3.74%, skull anteroposterior length by 8.92%, and skull nasio-occipital length by 7.87% compared with vehicle; increased foramen magnum transverse diameter by 13.05%, sagittal diameter by 9.28%, and area by 25.17% compared with vehicle. Improved the grade of skull base synchondroses, increased the size of hypertrophic zone chondrocytes (HZCs), increased proliferation of proliferating zone chondrocytes (PZCs), increased bone mineral density (BMD) by 21.4%, and increased bone volume-to-tissue volume ratio (BV/TV) by 73.3% compared with vehicle; increased L4-L6 lumbar vertebrae segment length by 23.49% compared with vehicle.
Animal Model: Tg-CMV^Cre/+ / Fgfr3^N534K/+ (mixed male and female, 3 days of age, Hypochondroplasia modeling)
Dosage: 1.8 mg/kg
Administration: s.c.; once daily; 21 days
Result: Increased femur length by 3.70%, tibia length by 3.75%, ulna length by 5.03%, and humerus length by 3.22% compared with vehicle-treated mutant mice.
Increased foramen magnum area by 7.51% and sagittal diameter by 6.35% compared with vehicle; reduced the grade of skull base synchondroses from grade V (completely fused) to grade IV (completely fused with cartilage margin remnants) in most mice and improved intervertebral disc shape compared with vehicle.
性状 固体
颜色 White to off-white

化学信息

分子量 559.47
分子式 C25H24Cl2N6O3S
CAS No. 2800223-30-5
别名 TYRA-300

储存&溶解度

体内实验配方
10% DMSO+90% Saline: < 10 mg/mL (17.87 mM), Lower concentrations may be soluble, but exact solubility limit is unknown.
10% DMSO+40% PEG300+5% Tween-80+45% Saline: 5 mg/mL (8.94 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (17.87 mM), Solution.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (178.74 mM; 超声助溶 (<60°C); 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM1.7874 mL8.9370 mL17.8741 mL44.6852 mL
5 mM0.3575 mL1.7874 mL3.5748 mL8.9370 mL
10 mM0.1787 mL0.8937 mL1.7874 mL4.4685 mL
15 mM0.1192 mL0.5958 mL1.1916 mL2.9790 mL
20 mM0.0894 mL0.4469 mL0.8937 mL2.2343 mL
25 mM0.0715 mL0.3575 mL0.7150 mL1.7874 mL
30 mM0.0596 mL0.2979 mL0.5958 mL1.4895 mL
40 mM0.0447 mL0.2234 mL0.4469 mL1.1171 mL
50 mM0.0357 mL0.1787 mL0.3575 mL0.8937 mL
60 mM0.0298 mL0.1490 mL0.2979 mL0.7448 mL
80 mM0.0223 mL0.1117 mL0.2234 mL0.5586 mL
100 mM0.0179 mL0.0894 mL0.1787 mL0.4469 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础